Let's make size not matter: tumor control and toxicity outcomes of hypofractionated Gamma Knife radiosurgery for large brain metastases
- PMID: 37410346
- DOI: 10.1007/s11060-023-04365-9
Let's make size not matter: tumor control and toxicity outcomes of hypofractionated Gamma Knife radiosurgery for large brain metastases
Abstract
Purpose: Management of patients with large brain metastases poses a clinical challenge, with poor local control and high risk of adverse radiation events when treated with single-fraction stereotactic radiosurgery (SF-SRS). Hypofractionated SRS (HF-SRS) may be considered, but clinical data remains limited, particularly with Gamma Knife (GK) radiosurgery. We report our experience with GK to deliver mask-based HF-SRS to brain metastases greater than 10 cc in volume and present our control and toxicity outcomes.
Methods: Patients who received hypofractionated GK radiosurgery (HF-GKRS) for the treatment of brain metastases greater than 10 cc between January 2017 and June 2022 were retrospectively identified. Local failure (LF) and adverse radiation events of CTCAE grade 2 or higher (ARE) were identified. Clinical, treatment, and radiological information was collected to identify parameters associated with clinical outcomes.
Results: Ninety lesions (in 78 patients) greater than 10 cc were identified. The median gross tumor volume was 16.0 cc (range 10.1-56.0 cc). Prior surgical resection was performed on 49 lesions (54.4%). Six- and 12-month LF rates were 7.3% and 17.6%; comparable ARE rates were 1.9% and 6.5%. In multivariate analysis, tumor volume larger than 33.5 cc (p = 0.029) and radioresistant histology (p = 0.047) were associated with increased risk of LF (p = 0.018). Target volume was not associated with increased risk of ARE (p = 0.511).
Conclusions: We present our institutional experience treating large brain metastases using mask-based HF-GKRS, representing one of the largest studies implementing this platform and technique. Our LF and ARE compare favorably with the literature, suggesting that target volumes less than 33.5 cc demonstrate excellent control rates with low ARE. Further investigation is needed to optimize treatment technique for larger tumors.
Keywords: Brain metastases; Gamma Knife; Hypofractionated; Radiosurgery; Tumor control.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.J Neurosurg. 2018 Aug;129(2):366-382. doi: 10.3171/2017.3.JNS162532. Epub 2017 Sep 22. J Neurosurg. 2018. PMID: 28937324
-
Hypofractionated stereotactic radiosurgery (HSRS) as a salvage treatment for brain metastases failing prior stereotactic radiosurgery (SRS).J Neurooncol. 2023 Mar;162(1):119-128. doi: 10.1007/s11060-023-04265-y. Epub 2023 Mar 13. J Neurooncol. 2023. PMID: 36914878
-
A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery for the treatment of brain metastasis.Radiat Oncol. 2020 May 28;15(1):128. doi: 10.1186/s13014-020-01522-6. Radiat Oncol. 2020. PMID: 32466775 Free PMC article.
-
Single- and hypofractionated stereotactic radiosurgery for large (> 2 cm) brain metastases: a systematic review.J Neurooncol. 2021 Aug;154(1):25-34. doi: 10.1007/s11060-021-03805-8. Epub 2021 Jul 15. J Neurooncol. 2021. PMID: 34268640
-
Hypofractionated versus single-fraction stereotactic radiosurgery for the treatment of brain metastases: A systematic review and meta-analysis.Clin Neurol Neurosurg. 2021 Jul;206:106645. doi: 10.1016/j.clineuro.2021.106645. Epub 2021 Apr 20. Clin Neurol Neurosurg. 2021. PMID: 33984752
Cited by
-
CNN-based multi-modal radiomics analysis of pseudo-CT utilization in MRI-only brain stereotactic radiotherapy: a feasibility study.BMC Cancer. 2024 Jan 10;24(1):59. doi: 10.1186/s12885-024-11844-3. BMC Cancer. 2024. PMID: 38200424 Free PMC article.
-
Upfront frameless hypofractionated gamma knife radiosurgery for large posterior Fossa metastases.Neurosurg Rev. 2025 May 15;48(1):418. doi: 10.1007/s10143-025-03572-4. Neurosurg Rev. 2025. PMID: 40372490 Free PMC article.
References
-
- Fox BD, Cheung VJ, Patel AJ et al (2011) Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 22:1–6. https://doi.org/10.1016/j.nec.2010.08.007 - DOI - PubMed
-
- Shaw E, Scott C, Souhami L et al (2000) Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90 – 05. Int J Radiat Oncol 47:291–298. https://doi.org/10.1016/S0360-3016(99)00507-6 - DOI
-
- Nieder C, Berberich W, Schnabel K (1997) Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol 39:25–30. https://doi.org/10.1016/S0360-3016(97)00154-5 - DOI
-
- Han JH, Kim DG, Chung H-T et al (2012) Radiosurgery for large brain metastases. Int J Radiat Oncol 83:113–120. https://doi.org/10.1016/j.ijrobp.2011.06.1965 - DOI
-
- Brown PD, Jaeckle K, Ballman KV et al (2016) Effect of Radiosurgery alone vs Radiosurgery with Whole Brain Radiation Therapy on cognitive function in patients with 1 to 3 brain metastases: a Randomized Clinical Trial. JAMA 316:401. https://doi.org/10.1001/jama.2016.9839 - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous